Multi Radiance researchers named to Stanford’s Top 2% Scientists List

Two long-standing Multi Radiance Medical (MRM) research team members, Ernesto Cesar Pinto Leal-Junior and Janis T. Eells, have been named to the 2025 Stanford University Top 2% Scientists List for their work in the field of photobiomodulation research.

MRM’s commitment to research has led to the company receiving multiple FDA clearances for musculoskeletal pain and indications for neck and shoulder pain and fibromyalgia pain, a unique feat in the therapeutic laser industry.

Stanford’s highly respected ranking identifies the most cited scholars in their fields, the world’s leading researchers whose work has had a significant impact across various scientific disciplines, representing approximately 2% of all scientists.

For more than 12 years, Leal-Junior has authored numerous peer-reviewed clinical studies. According to the independent, international Physiotherapy Evidence Database (PEDro), there are 49,722 randomized controlled trials (RCTs) listed, of which only 61 have achieved a perfect 10 score. Leal-Junior is author or co-author of 13 of these trials, representing 21% of all perfect-score RCTs in the database. This reflects an independent, internationally recognized benchmark of methodological rigor.

Ernesto Cesar Pinto Leal-Junior, PhD, MSc, PT

“Our work continues to demonstrate that sustained, rigorous scientific methodology is essential to producing light-based medical devices that deliver reproducible outcomes,” said Leal-Junior.

A member of MRM’s Medical Advisory board since 2015, Eells pioneered investigations into the mechanism of action and therapeutic application of photobiomodulation in the treatment of retinal injury and retinal disease.

“Exposing the retina to far-red to near infrared light does far more than illuminate; it reinvigorates the failing photoreceptor bioenergetics, quiets inflammation and opens a path for vision to endure when degeneration once seemed inevitable,” said Eells.

Evidence informs product development

Thanks to the contributions of researchers like Leal-Junior and Eells, MRM can translate independent scientific evidence directly into product development.

“Our development pipeline is driven by evidence, not assumptions,” said Douglas Johnson, MRM Chief Science Officer. “Clinicians trust us because we build technology on real data and repeatable research models.”

“We remain committed to bringing research-validated therapeutic solutions to providers across the world,” said Max Kanarsky, MRM President and CEO. “Our partnerships reflect the scientific standards we believe should define this category.”

For more information, visit multiradiance.com.

About Multi Radiance Medical

Multi Radiance Medical develops and manufactures and distributes FDA-cleared energy-based therapeutic technologies including Super Pulsed Laser, high-power laser, shockwave therapy, TECAR therapy and thermal imaging. The company has served rehabilitation, chiropractic, physiatry, sports medicine and veterinary markets for 20 years, and the technology is utilized in more than 30 countries.